SlideShare a Scribd company logo
1 of 41
Carcinoma Esophagus
Presented By:
Dr. Ayush Garg
AJCC TNM classification
❚ a: Includes nodes
previously labeled as
“M1a”
❚ b : “M1a” designation is
no longer recognized in
the 7th edn. of the AJCC
system
Staging : Squamous cell
carcinoma
Staging : Adenocarcinoma
Group T N M Grade
0 Tis (HGD)
N0
M0
1, X
IA T1 1-2, X
IB T1 3
T2 1-2, X
IIA T2 3
IIB T3
T1-2 N1
IIIA T1-2 N2
T3 N1
T4a N0 Any
IIIB T3 N2
IIIC T4a N1-2
T4b Any
Any N3
IV Any Any M1
Diagnostic Workup
❚ Detailed history & Physical examination: Dysphagia,
odynophagia, hoarseness, wt. loss, use of tobacco, nitrosamines,
history of GERD. Examine for cervical or supraclavicular adenopathy.
❚ Confirmation of diagnosis:
❙ EGD: allow direct visualization and biopsy, measure proximal & distal distance of
tumor from incisor, presence of Barrett’s esophagus.
Early, superficial
cancer
Circumferential ulceration
esophageal cancer
Malignant stricture
of esophagus
❚Staging:
❙ CT chest and abdomen: Essential for staging because it can identify extension
beyond the esophageal wall, enlarged lymph nodes and visceral metastases.
Figure Esophageal cancer with tracheal invasion. CT
scan shows circumferential wall thickening of the
proximal esophagus (arrowheads), which shows
irregular interface with the posterior wall of the trachea
(arrows), indicating direct extension into the lumen
Figure Esophageal cancer with aortic invasion. An
arc (bent arrow) of the contact between
esophageal cancer (arrows) and the
the
aorta
(arrowheads) is more than 90 degrees, indicating
aortic invasion.
Endoscopic Ultrasonography
❚ EUS:
❙ assess the depth of penetration and LN involvement. Limited by the degree of
obstruction.
❙ Compared with EUS, CT is not a reliable tool for evaluation of the extent of
tumor in the esophageal wall.
Fig. —55-year-old man with T2 esophageal tumor (m)
shown on endoscopic sonogram. Note alternating
hyperechoic and hypoechoic layers (arrowheads) of normal
esophageal wall as seen on sonography. Innermost layer is
hyperechoic and corresponds to superficial mucosa. Second
layer is hypoechoic and corresponds to deep mucosa and
muscularis mucosae. Third layer is again hyperechoic and
corresponds to submucosa and its interface with muscularis
propria. Fourth layer is hypoechoic and corresponds to
muscularis propria, and outer fifth layer is hyperechoic and
corresponds to adventitia.
PET Scan
❚ most recently, proven to be valuable staging tool
❚ can detect up to 15–20% of metastases not seen on CT and EUS
❚ low accuracy in detecting local nodal disease compared to CT / EUS
❚ Value in evaluating response to Chemo Therapy & Radio Therapy
❚ addition of PET to CT can improve specificity and accuracy of non-
invasive staging
Figure Distant lymph node metastases of esophageal cancer detected by integrated CT PET. A, Integrated CT
PET demonstrates para-aortic lymph node metastases showing increased FDG uptake (arrowheads). B,
Corresponding CT image shows lymph nodes (arrowheads) measuring 5 to 8 mm in diameter. Based on size
criteria, these lymph nodes may be considered benign on CT scan
❚ Barium swallow:
❙ can delineate proximal and distal margins as well as TEF
❙ Helpful for correlation with simulation film.
❚ Bronchoscopy: rule-out fistula in midesophageal lesions.
❚Routine Investigations: CBC, chemistries, LFTs.
Cancer lower 1/3
Filling defect (ulcerative type)Rat tail appearance
Apple core appearance
Figure: A proposed treatment
algorithm for esophageal cancer.
Treatment
Management depends upon:
❚ Site of disease
❚ Extent of disease involvement
❚ Co-morbid conditions
❚ Patient preference.
Surgery
❚ Prerequisite for surgery
❙ disease should be 5 cm beyond cricophyrangeus.
❚ Surgery indications
❙ Lower 1/3 rd oesophageal ds involving GE junction.
❙ Tumor size <5 cm .
❙ palliative surgery
❚ 5-Year OS for surgery alone is 20–25% (no significant difference
between surgical techniques according to results of 2 meta-analyses)
❚ Local failure rate around 19–57% when used alone
❚ surgical morbidity/mortality related to experience of the surgeons.
Types of Surgery
❚ Transhiatal esophagectomy: for tumors anywhere in esophagus or
gastric cardia. No thoracotomy. Blunt dissection of the thoracic esophagus.
Left with cervical anastomosis. Limitations are lack of exposure of
midesophagus and direct visualization and dissection of the subcarinal LN
cannot be performed.
❚ Right thoracotomy (Ivor-Lewis procedure): good for exposure of mid
to upper esophageal lesions. Left with thoracic or cervical anastomosis.
❚ Left thoracotomy: appropriate for lower third of esophagus and gastric
cardia. Left with low-to-midthoracic anastomosis.
❚ Radical (en block) resection: for tumor anywhere in esophagus or
gastric cardia. Left with cervical or thoracic anastomosis. Benefit is more
extensive lymphadenectomy and potentially better survival, but increased
operative risk.
Chemotherapy
❚ No data proving that chemotherapy alone provides improved
survival or palliation. Partial response, not long-term remission, is
the rule
❚Indication
❙ Used in combination with radiation for locally advancedcancers
❙ Used as single treatment modality in stage IVdisease
❙ Combination chemotherapy has been used preoperatively in a combined
modality approach to esophageal Ca in hopes of controlling occult metastatic
disease and improving the resectability rate.
❚ Platinum doublet is preferred over single agents
❚ Cisplatin plus 5-FU or docetaxel are commonly used combinations
Regimens:
❚ Paclitaxel and carboplatin
❚ Cisplatin and 5-FU or capecitabine
❚ Oxaliplatin and 5-FU or capecitabine
❚ Paclitaxel or docetaxel and cisplatin
❚ Carboplatin and 5-FU
❚ Irinotecan and cisplatin
❚ Oxaliplatin, docetaxel and capecitabine
❚ Epirubicin, cisplatin and 5-FU (Only for adenocarcinoma)
Radiotherapy
❚Curative
❙Radical RT
❙Pre-Op RT
❙Post Op RT
❙Concurrent chemo-radiation
❚Palliative
❚EBRT
❚Brachytherapy
EBRT Techniques
❚ Patient Positioning:
❙ CERVICAL ESOPHAGUS: Supine with arms by the side
❙ MID AND LOWER THIRD:
❘ SUPINE With arms above their head if AP – PA portals are being planned
❘ PRONE if posterior obliques are beingincluded.
• Esophagus is pulled anteriorly and spinal cord can be spared.
❚
❚
IMMOBILISATION :
❙ Perspex cast
❙ Vertebral column should be as parallel to couch as possible.
Barium swallow contrast to delineate the esophageal lumen and
stomach.
EBRT – Cervical Esophagus
Field Portals:
❚ AP – PA foll. by opposed oblique pair.
❚ 2 anterior obliques and 1 posterior field.
❚ 2 posterior obliques and 1 anterior field
❚ 4 field box with soft tissue compensators foll by obliques ( Univ of
Florida tech )
❚ SUPERIOR BORDER: At C 7
❚ INFERIOR BORDER : At T 4 ( carina )
❚ 2 cm lateral margins.
❚ SC nodes irradiated electively.
❚ SC nodes will be underdosed if oblique portals are used to treat
primary; can be boosted by a separate field if required.
EBRT – Mid & Lower1/3rd
 AP – PA followed by 1 Ant and 2 Post oblique pair
 4 FIELD : AP-PA & opposed laterals – for mid 1/3rd lesions with
patient in prone position.
 AP-PA upto 43 Gy foll by 2 Post obliques upto 50 Gy ( gross disease
boosted to 60 Gy )
❚ SUPERIOR BORDER: 5 cm proximal to superior extent of disease.
❚ INFERIOR BORDER:
❙ MID 1/3RD – AT GE jn. As visualised by Barium swallow
❙ LOWER 1/3RD - Coeliac plexus ( L 1 ) to be included.
Radiotherapy for
CA esophagus
EBRT - DOSES
❚ Energy
❙ 6 – 10 MV linac orCo60
❚ Chemoradiation:
❙ 50.4 Gy in 28 # at 1.8 Gy per #
❙ Boost to 60 – 66 Gy for residual disease
❚ Radical RT:
❙ 45 Gy / 25 # / 1.8 Gy per #
❙ boost with 2 cm margin to total dose of 60Gy
❚ Dose limitations
❙ Spinal cord Dmax:45 Gy at 1.8 Gy/fx
❙ Lung: Limit 70% of both lungs <20 Gy
❙ Heart: Limit 50% of ventricles <25 Gy
Brachytherapy (Intraluminal)
❚ As a boost after EBRT or as a palliative measure
❚ Local control of 25% - 35 in palliative setting
❚ In curative setting, addition of brachytherapy does not improve
results compared to Chemoradiation.
❚ Limit dose to critical structure
❚ Dose escalation to primary
❚ Relief bleeding, pain and improves swallowing status in palliative
setting.
American Brachytherapy
Society Guidelines
Patient selection:
❙ Primary tumor length ≤ 10 cm length
❙ Tumor confined to esophagealwall
❙ Thoracic esophaguslocation
❙ No nodal / systemicmetastasis.
Contraindications:
❙ T Efistula
❙ Cervical esophagouslocation
❙ Stenosis which cannot bebypassed
Contd…
❚
❚
❚
❚
EBRT 45 – 50 Gy in 1.8-2.0Gy /#,5#/wk
❘ HDR – 5 Gy x two # one week apart , 2 – 3weeks after EBRT.
❘ LDR – single 20 Gy # @ 0.4 – 1.0 Gy per hr, 2 -3 weeks after EBRT.
Never concurrently with chemotherapy
Ext diameter of applicator must be 6 – 10 mm.
Active length : visible tumor by UGI scopy plus 1 – 2 cm proximal &
distal margin.
❚ Dose is prescribed 1 cm from mid source or mid dwell position.
APPLICATORS
Trials – RT alone
❚ No randomized trials of RT VsSx
❚ 5 yr survival with conventional RT : < 10%
❚ Tumors < 5 cm , 5 yr survival :20%
❚ Stage wise 5 yrsurvival:
❙ Stage I –20%
❙ Stage II –10%
❙ Stage III – 3%
❙ Stage IV –0%
Contd…
❚ For cervical esophagus, cure rates were similar with Radical RT or
Sx alone.
❚ RT or Sx alone DOES NOT alter the natural history of the disease.
❚ RTOG 8501: RT Vs Chemo RT
❙ Better LRC and improved OS with ChemoRT
 RT alone should be used for palliation or in medically unfit patients.
Trials– PreOP RT
❚Principle:
❙  resectability,  likelihood of tumor dissemination during Sx ,
 radioresponsiveness due to unaltered blood supply
❙ 5 randomised trials ,shows no apparent clinical benefit to use
of preop rt alone except,
❙ Only one trial ( Huang et al ) showed survival advantage of
46% Vs 25% with 40 Gy RT
❙ Recent meta analysis Oesophageal Cancer Collaborative Group
study showed no clear survival advantage.
 No difference in resectability rates, LRC or survival with pre-op RT
Trials– PostOP RT
❚Advantages:
❙ Treat areas at risk for recurrences while minimizing
dose to OAR.
❙ Patients with node negative , completely resected T1
/ T2 tumors can be excluded.
stomach or bowel used for
❚ Disadvantage:
❙Tolerance of
interpositioning.
Contd…
• ❚ 2 randomised trials:
• ❙ Peniere et al:-
• ❘ 221 pts, mid / low 1/3rd growth
• ❘ RT : 45- 55 Gy @ 1.8 Gy per #
• ❘ 3 yrs -  local failure rate ( from 35% to 10%)
• - no significant disease free survival.
• ❙ Fok et al:-
• ❘ 130 pts , RT – 49 Gy @ 3.5 Gy per #
• ❘ Local failure rate  in patients who had palliative
resection ( from 46% to 20% )
• ❘ No difference for completely resected patients
•  Post op RT improves localcontrol, but does
not confer any survival advantage.
ChemoRT followed Sx
Vs.ChemoRT
❚ Patient undergoing surgery
have worse quality of life.
❚ Surgery following combined
CRT appears to improve
local control, its impact on
ultimate survival remains
controversial.
Trials– Chemoradiation
ChemoRT Vs RT Alone
❚ RTOG 8501 INTERGROUP TRIAL:
❙ 121 pts: 60 pts RT alone – 64 Gy @ 2 Gy per #
61 pts chemoRT – 50 Gy RT +
5 FU + CDDP – on 1 , 5 , 8 & 11 weeks
❙ Median survival : 8.9 Vs 12.5 months
❙ 5 yr survival : 0% Vs 30 %
❙ Distant mets @ 5 yrs: 40% Vs 12 %
❙ Acute toxicity : 25% Vs 44 %
❚  Median & overall survival, LRR and Acute toxicity in Chemo RT
arm.
 Chemoradiation is a standard Non-surgical Tx.
Contd…
RT dose escalation in Chemo RT
❚ Intergroup 0123 TRIAL – 218 pts
❙ Chemoradiation - either 50.4 Gy or 64.8Gy
❙ No significant difference in median survival, 2 yr survival or loco-
regional failure.
 Intensification of RT dose beyond 50.4 Gy(in combination with
chemotherapy ) does not improve results.
Contd…
Sx ALONEPRE OP CHEMO RT Vs
❚ 44 Randomised trials
❚ 2 studies showed  in local recurrence
❙ Urba et al – 19 % Vs 42 %
❙ Bosset et al ( EORTC ) – 28% Vs 40%
❚ One study showed significant survival benefit at 3 yrs (in pts who had
a pathologic CR )
❙ Urba et al – 64% Vs 19%
❚ One study (Walsh et al) showed benefit in median (16 Vs 11 months )
and overall survival at 3 yrs ( 32 Vs 6%)
 Results support TRIMODALITY approach.
Pre-operative Chemotherapy
The role of preoperative
chemotherapy alone is
controversial, according to
mixed results from clinical
trials.
Stage Recommended treatment
Stage I–III and IVA
resectable
medically-fit
definitive chemo-RT (preferred for cervical esophagus)
Or, Pre-op chemo-RT →surgery. Surgery preferred for adenocarcinoma
regardless of response to chemo-RT.
Or, surgery. (noncervical T1N0 and young T2N0 patients with primaries
of lower esophagus or gastroesophageal junction.
Indications for post-op chemo-RT include: unfavorable T2N0, T3/4,
LN+, and/or close/+ margin.
Stage I–III inoperable Definitive chemo-RT
Stage IV palliative Concurrent chemo-RT (5-FU + cisplatin, 50 Gy) or RT alone (e.g., 2.5
Gy × 14 fx) or chemo alone or best supportive care.
Pain: medications ± RT
Bleeding: endoscopic therapy, surgery, or RT
Current approach
❚ EBRT using 3D-CRT to a total dose of 50.4 Gy (1.8 Gy per daily fraction) is
standard.
❚ IMRT is often utilized to minimize exposure to adjacent structures.
❚ Proton beam in combination with chemotherapy is being explored.
❚ Targeted biologic agents added to standard cytotoxic chemotherapy is
being explored
Conclusion
❚ Esophageal cancer is the 7th leading cause of cancer deaths.
❚ Adenocarcinoma now accounts for over 50% of esophageal cancer in the
USA, due to association with GERD & obesity.
❚ Dysphagia and weight loss are the two most common presentations in
patients with esophageal cancer.
❚ Endoscopic ultrasound (EUS) is necessary to accompany a complete workup
for proper staging and diagnosis of esophageal cancer.
❚ Surgery is the standard of care for early-stage esophageal cancer.
❚ Preoperative chemotherapy and radiation is the standard option for locally
advanced esophageal cancer in surgically eligible patients.
Thank You

More Related Content

What's hot

Contouring Guidelines for Gynecological Malignancy
Contouring Guidelines for Gynecological MalignancyContouring Guidelines for Gynecological Malignancy
Contouring Guidelines for Gynecological MalignancyJyotirup Goswami
 
Esophagus cancer radiation treatment
Esophagus cancer radiation treatmentEsophagus cancer radiation treatment
Esophagus cancer radiation treatmentRobert J Miller MD
 
RAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUMRAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUMKanhu Charan
 
Cervix External Beam Radiotherapy techniques
Cervix External Beam Radiotherapy techniquesCervix External Beam Radiotherapy techniques
Cervix External Beam Radiotherapy techniquesAnimesh Agrawal
 
Radiotherapy for bladder cancers
Radiotherapy for bladder cancersRadiotherapy for bladder cancers
Radiotherapy for bladder cancersAshutosh Mukherji
 
Management of testicular tumors-Seminoma (by Dr. Akhil Kapoor)
Management of testicular tumors-Seminoma (by Dr. Akhil Kapoor)Management of testicular tumors-Seminoma (by Dr. Akhil Kapoor)
Management of testicular tumors-Seminoma (by Dr. Akhil Kapoor)Akhil Kapoor
 
Radiation for Colon and Rectal Cancer
Radiation for Colon and Rectal CancerRadiation for Colon and Rectal Cancer
Radiation for Colon and Rectal CancerRobert J Miller MD
 
Carcinoma cervix brachytherapy- dr upasna
Carcinoma cervix   brachytherapy- dr upasnaCarcinoma cervix   brachytherapy- dr upasna
Carcinoma cervix brachytherapy- dr upasnaUpasna Saxena
 
Management of prostate cancer
Management of prostate cancerManagement of prostate cancer
Management of prostate cancerdamuluri ramu
 
Management of Rectal Cancer
Management of Rectal CancerManagement of Rectal Cancer
Management of Rectal CancerSubhash Thakur
 
Ca Nasopharynx contouring.pptx
Ca Nasopharynx contouring.pptxCa Nasopharynx contouring.pptx
Ca Nasopharynx contouring.pptxSayan Das
 
Head and neck reirradiation
Head and neck reirradiationHead and neck reirradiation
Head and neck reirradiationKanhu Charan
 
ICRU 89 summary & beyond converted
ICRU 89 summary & beyond convertedICRU 89 summary & beyond converted
ICRU 89 summary & beyond convertedDr. Abhishek Basu
 

What's hot (20)

Contouring Guidelines for Gynecological Malignancy
Contouring Guidelines for Gynecological MalignancyContouring Guidelines for Gynecological Malignancy
Contouring Guidelines for Gynecological Malignancy
 
Radiation therapy in wilms tumour
Radiation therapy in wilms tumourRadiation therapy in wilms tumour
Radiation therapy in wilms tumour
 
Rt techniques in lymphoma
Rt techniques in lymphomaRt techniques in lymphoma
Rt techniques in lymphoma
 
RT in Ca Esophagus
RT in Ca EsophagusRT in Ca Esophagus
RT in Ca Esophagus
 
Esophagus cancer radiation treatment
Esophagus cancer radiation treatmentEsophagus cancer radiation treatment
Esophagus cancer radiation treatment
 
RAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUMRAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUM
 
Cervix External Beam Radiotherapy techniques
Cervix External Beam Radiotherapy techniquesCervix External Beam Radiotherapy techniques
Cervix External Beam Radiotherapy techniques
 
Radiotherapy for bladder cancers
Radiotherapy for bladder cancersRadiotherapy for bladder cancers
Radiotherapy for bladder cancers
 
Management of testicular tumors-Seminoma (by Dr. Akhil Kapoor)
Management of testicular tumors-Seminoma (by Dr. Akhil Kapoor)Management of testicular tumors-Seminoma (by Dr. Akhil Kapoor)
Management of testicular tumors-Seminoma (by Dr. Akhil Kapoor)
 
Radiation for Colon and Rectal Cancer
Radiation for Colon and Rectal CancerRadiation for Colon and Rectal Cancer
Radiation for Colon and Rectal Cancer
 
Carcinoma cervix brachytherapy- dr upasna
Carcinoma cervix   brachytherapy- dr upasnaCarcinoma cervix   brachytherapy- dr upasna
Carcinoma cervix brachytherapy- dr upasna
 
Carcinoma of unknown primary
Carcinoma of unknown primaryCarcinoma of unknown primary
Carcinoma of unknown primary
 
ORAL CAVITY.pptx
ORAL CAVITY.pptxORAL CAVITY.pptx
ORAL CAVITY.pptx
 
Trials in esophageal cancer.pptx
Trials in esophageal cancer.pptxTrials in esophageal cancer.pptx
Trials in esophageal cancer.pptx
 
Management of prostate cancer
Management of prostate cancerManagement of prostate cancer
Management of prostate cancer
 
Management of Rectal Cancer
Management of Rectal CancerManagement of Rectal Cancer
Management of Rectal Cancer
 
SBRT prostate
SBRT prostate SBRT prostate
SBRT prostate
 
Ca Nasopharynx contouring.pptx
Ca Nasopharynx contouring.pptxCa Nasopharynx contouring.pptx
Ca Nasopharynx contouring.pptx
 
Head and neck reirradiation
Head and neck reirradiationHead and neck reirradiation
Head and neck reirradiation
 
ICRU 89 summary & beyond converted
ICRU 89 summary & beyond convertedICRU 89 summary & beyond converted
ICRU 89 summary & beyond converted
 

Similar to Carcinoma esophagus

Carcinoma oesophagus
Carcinoma oesophagus Carcinoma oesophagus
Carcinoma oesophagus Silah Aysha
 
Esophagectomy : APPROACHES, CONTROVERSIES AND CURRENT EVIDENCE
Esophagectomy : APPROACHES, CONTROVERSIES AND CURRENT EVIDENCEEsophagectomy : APPROACHES, CONTROVERSIES AND CURRENT EVIDENCE
Esophagectomy : APPROACHES, CONTROVERSIES AND CURRENT EVIDENCEDr Amit Dangi
 
veerucapancreas-170124145806 (1).pptx
veerucapancreas-170124145806 (1).pptxveerucapancreas-170124145806 (1).pptx
veerucapancreas-170124145806 (1).pptxDanishMandi
 
Pancreatic cancer Management (pancreatic adenocarcinoma)
Pancreatic cancer Management (pancreatic adenocarcinoma)Pancreatic cancer Management (pancreatic adenocarcinoma)
Pancreatic cancer Management (pancreatic adenocarcinoma)Dr mohamed Salat Gonjobe
 
gastriccancer.ppt
gastriccancer.pptgastriccancer.ppt
gastriccancer.pptKhalidfadol
 
gastriccancer.ppt
gastriccancer.pptgastriccancer.ppt
gastriccancer.pptKhalidfadol
 
gastriccancer.ppt
gastriccancer.pptgastriccancer.ppt
gastriccancer.pptTyronBn
 
gastriccancer types classified and manage
gastriccancer types classified and managegastriccancer types classified and manage
gastriccancer types classified and manageShehinSalim3
 
Second Year Surgery Case Presentation
Second Year Surgery Case PresentationSecond Year Surgery Case Presentation
Second Year Surgery Case Presentationjnpeacoc
 
Recent update on oesophageal and gastric malignancy
Recent update on oesophageal and gastric malignancy Recent update on oesophageal and gastric malignancy
Recent update on oesophageal and gastric malignancy Emran PK
 
Management of Carcinoma Urinary Bladder by Dr Manas Dubey
Management of Carcinoma Urinary Bladder by Dr Manas DubeyManagement of Carcinoma Urinary Bladder by Dr Manas Dubey
Management of Carcinoma Urinary Bladder by Dr Manas DubeyDr Manas Dubey
 
Management of endometrial carcinoma
Management of endometrial carcinomaManagement of endometrial carcinoma
Management of endometrial carcinomaSailendra Parida
 
Management of Locally advanced NSCLC
Management of Locally advanced NSCLCManagement of Locally advanced NSCLC
Management of Locally advanced NSCLCDr Boaz Vincent
 
Vaginal SCC in Pelvic Organ Prolapse.pptx
Vaginal SCC in Pelvic Organ Prolapse.pptxVaginal SCC in Pelvic Organ Prolapse.pptx
Vaginal SCC in Pelvic Organ Prolapse.pptxKirithaRanjani1
 

Similar to Carcinoma esophagus (20)

Carcinoma oesophagus
Carcinoma oesophagus Carcinoma oesophagus
Carcinoma oesophagus
 
Management of ca endometrium
Management of ca endometriumManagement of ca endometrium
Management of ca endometrium
 
Esophagectomy : APPROACHES, CONTROVERSIES AND CURRENT EVIDENCE
Esophagectomy : APPROACHES, CONTROVERSIES AND CURRENT EVIDENCEEsophagectomy : APPROACHES, CONTROVERSIES AND CURRENT EVIDENCE
Esophagectomy : APPROACHES, CONTROVERSIES AND CURRENT EVIDENCE
 
Ca stomach
Ca stomachCa stomach
Ca stomach
 
Esophagectomy
Esophagectomy Esophagectomy
Esophagectomy
 
veerucapancreas-170124145806 (1).pptx
veerucapancreas-170124145806 (1).pptxveerucapancreas-170124145806 (1).pptx
veerucapancreas-170124145806 (1).pptx
 
Pancreatic cancer Management (pancreatic adenocarcinoma)
Pancreatic cancer Management (pancreatic adenocarcinoma)Pancreatic cancer Management (pancreatic adenocarcinoma)
Pancreatic cancer Management (pancreatic adenocarcinoma)
 
gastriccancer.ppt
gastriccancer.pptgastriccancer.ppt
gastriccancer.ppt
 
gastriccancer.ppt
gastriccancer.pptgastriccancer.ppt
gastriccancer.ppt
 
gastriccancer.ppt
gastriccancer.pptgastriccancer.ppt
gastriccancer.ppt
 
gastriccancer types classified and manage
gastriccancer types classified and managegastriccancer types classified and manage
gastriccancer types classified and manage
 
Second Year Surgery Case Presentation
Second Year Surgery Case PresentationSecond Year Surgery Case Presentation
Second Year Surgery Case Presentation
 
Radiotherapy in carcinoma stomach - current scenario
Radiotherapy in carcinoma stomach - current scenarioRadiotherapy in carcinoma stomach - current scenario
Radiotherapy in carcinoma stomach - current scenario
 
Rectal carcinoma approach
Rectal carcinoma approachRectal carcinoma approach
Rectal carcinoma approach
 
Recent update on oesophageal and gastric malignancy
Recent update on oesophageal and gastric malignancy Recent update on oesophageal and gastric malignancy
Recent update on oesophageal and gastric malignancy
 
Retroperitoneal sarcoma
Retroperitoneal sarcomaRetroperitoneal sarcoma
Retroperitoneal sarcoma
 
Management of Carcinoma Urinary Bladder by Dr Manas Dubey
Management of Carcinoma Urinary Bladder by Dr Manas DubeyManagement of Carcinoma Urinary Bladder by Dr Manas Dubey
Management of Carcinoma Urinary Bladder by Dr Manas Dubey
 
Management of endometrial carcinoma
Management of endometrial carcinomaManagement of endometrial carcinoma
Management of endometrial carcinoma
 
Management of Locally advanced NSCLC
Management of Locally advanced NSCLCManagement of Locally advanced NSCLC
Management of Locally advanced NSCLC
 
Vaginal SCC in Pelvic Organ Prolapse.pptx
Vaginal SCC in Pelvic Organ Prolapse.pptxVaginal SCC in Pelvic Organ Prolapse.pptx
Vaginal SCC in Pelvic Organ Prolapse.pptx
 

More from DrAyush Garg

Overview of Carcinoma Prostate and Genetics
Overview of Carcinoma Prostate and GeneticsOverview of Carcinoma Prostate and Genetics
Overview of Carcinoma Prostate and GeneticsDrAyush Garg
 
Overview of brain tumors
Overview of brain tumorsOverview of brain tumors
Overview of brain tumorsDrAyush Garg
 
Hormonal therapy in breast cancer
Hormonal therapy in breast cancerHormonal therapy in breast cancer
Hormonal therapy in breast cancerDrAyush Garg
 
Role of palliative care in oncology
Role of palliative care in oncologyRole of palliative care in oncology
Role of palliative care in oncologyDrAyush Garg
 
Breast cancer screening, prevention and genetic counselling
Breast cancer screening, prevention and genetic counsellingBreast cancer screening, prevention and genetic counselling
Breast cancer screening, prevention and genetic counsellingDrAyush Garg
 
Role of SBRT in lung cancer
Role of SBRT in lung cancerRole of SBRT in lung cancer
Role of SBRT in lung cancerDrAyush Garg
 
Role of hpv in head and neck tumors
Role of hpv in head and neck tumorsRole of hpv in head and neck tumors
Role of hpv in head and neck tumorsDrAyush Garg
 
Cancer vaccines final
Cancer vaccines finalCancer vaccines final
Cancer vaccines finalDrAyush Garg
 
EXTRANODAL EXTENSION
EXTRANODAL EXTENSIONEXTRANODAL EXTENSION
EXTRANODAL EXTENSIONDrAyush Garg
 
Management of ca prostate
Management of ca prostateManagement of ca prostate
Management of ca prostateDrAyush Garg
 
Clinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma ProstateClinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma ProstateDrAyush Garg
 
Prognostic index in brain metastasis
Prognostic index in brain metastasisPrognostic index in brain metastasis
Prognostic index in brain metastasisDrAyush Garg
 
Supportive care and quality of life
Supportive care and quality of lifeSupportive care and quality of life
Supportive care and quality of lifeDrAyush Garg
 
Palliation brain, spinal and bone mets
Palliation brain, spinal and bone metsPalliation brain, spinal and bone mets
Palliation brain, spinal and bone metsDrAyush Garg
 
Small cell lung cancer
Small cell lung cancerSmall cell lung cancer
Small cell lung cancerDrAyush Garg
 

More from DrAyush Garg (20)

Overview of Carcinoma Prostate and Genetics
Overview of Carcinoma Prostate and GeneticsOverview of Carcinoma Prostate and Genetics
Overview of Carcinoma Prostate and Genetics
 
OSTEOSARCOMA
OSTEOSARCOMAOSTEOSARCOMA
OSTEOSARCOMA
 
Overview of brain tumors
Overview of brain tumorsOverview of brain tumors
Overview of brain tumors
 
Hormonal therapy in breast cancer
Hormonal therapy in breast cancerHormonal therapy in breast cancer
Hormonal therapy in breast cancer
 
Multiple myeloma
Multiple myelomaMultiple myeloma
Multiple myeloma
 
Ear carcinoma
Ear carcinomaEar carcinoma
Ear carcinoma
 
Medulloblastoma
MedulloblastomaMedulloblastoma
Medulloblastoma
 
Role of palliative care in oncology
Role of palliative care in oncologyRole of palliative care in oncology
Role of palliative care in oncology
 
Breast cancer screening, prevention and genetic counselling
Breast cancer screening, prevention and genetic counsellingBreast cancer screening, prevention and genetic counselling
Breast cancer screening, prevention and genetic counselling
 
Role of SBRT in lung cancer
Role of SBRT in lung cancerRole of SBRT in lung cancer
Role of SBRT in lung cancer
 
Role of hpv in head and neck tumors
Role of hpv in head and neck tumorsRole of hpv in head and neck tumors
Role of hpv in head and neck tumors
 
Cancer vaccines final
Cancer vaccines finalCancer vaccines final
Cancer vaccines final
 
EXTRANODAL EXTENSION
EXTRANODAL EXTENSIONEXTRANODAL EXTENSION
EXTRANODAL EXTENSION
 
Management of ca prostate
Management of ca prostateManagement of ca prostate
Management of ca prostate
 
Clinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma ProstateClinical Trials in Carcinoma Prostate
Clinical Trials in Carcinoma Prostate
 
Prognostic index in brain metastasis
Prognostic index in brain metastasisPrognostic index in brain metastasis
Prognostic index in brain metastasis
 
Supportive care and quality of life
Supportive care and quality of lifeSupportive care and quality of life
Supportive care and quality of life
 
Palliation brain, spinal and bone mets
Palliation brain, spinal and bone metsPalliation brain, spinal and bone mets
Palliation brain, spinal and bone mets
 
Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
 
Small cell lung cancer
Small cell lung cancerSmall cell lung cancer
Small cell lung cancer
 

Recently uploaded

Results For Love Spell Is Guaranteed In 1 Day +27834335081 [BACK LOST LOVE SP...
Results For Love Spell Is Guaranteed In 1 Day +27834335081 [BACK LOST LOVE SP...Results For Love Spell Is Guaranteed In 1 Day +27834335081 [BACK LOST LOVE SP...
Results For Love Spell Is Guaranteed In 1 Day +27834335081 [BACK LOST LOVE SP...BabaJohn3
 
Dermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdfDermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdfniloofarbarzegari76
 
Varicose Veins Treatment Aftercare Tips by Gokuldas Hospital
Varicose Veins Treatment Aftercare Tips by Gokuldas HospitalVaricose Veins Treatment Aftercare Tips by Gokuldas Hospital
Varicose Veins Treatment Aftercare Tips by Gokuldas HospitalGokuldas Hospital
 
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...marcuskenyatta275
 
Vip ℂall Girls Shalimar Bagh Phone No 9999965857 High Profile ℂall Girl Delhi...
Vip ℂall Girls Shalimar Bagh Phone No 9999965857 High Profile ℂall Girl Delhi...Vip ℂall Girls Shalimar Bagh Phone No 9999965857 High Profile ℂall Girl Delhi...
Vip ℂall Girls Shalimar Bagh Phone No 9999965857 High Profile ℂall Girl Delhi...jiyav969
 
Treatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas HospitalTreatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas HospitalGokuldas Hospital
 
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...Ayman Seddik
 
Quality control tests of suppository ...
Quality control tests  of suppository ...Quality control tests  of suppository ...
Quality control tests of suppository ...Hasnat Tariq
 
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerSherrylee83
 
VIP Pune 7877925207 WhatsApp: Me All Time Serviℂe Available Day and Night
VIP Pune 7877925207 WhatsApp: Me All Time Serviℂe Available Day and NightVIP Pune 7877925207 WhatsApp: Me All Time Serviℂe Available Day and Night
VIP Pune 7877925207 WhatsApp: Me All Time Serviℂe Available Day and Nightpatanjali9823#S07
 
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATROROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATROKanhu Charan
 
Let's Talk About It: Ovarian Cancer (The Emotional Toll of Treatment Decision...
Let's Talk About It: Ovarian Cancer (The Emotional Toll of Treatment Decision...Let's Talk About It: Ovarian Cancer (The Emotional Toll of Treatment Decision...
Let's Talk About It: Ovarian Cancer (The Emotional Toll of Treatment Decision...bkling
 
The Clean Living Project Episode 24 - Subconscious
The Clean Living Project Episode 24 - SubconsciousThe Clean Living Project Episode 24 - Subconscious
The Clean Living Project Episode 24 - SubconsciousThe Clean Living Project
 
Video capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in childrenVideo capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in childrenRaju678948
 
Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answersShafnaP5
 
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...marcuskenyatta275
 
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptxThe Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptxDr. Rabia Inam Gandapore
 
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.GawadHemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.GawadNephroTube - Dr.Gawad
 
Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?
Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?
Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?DrShinyKajal
 
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdfSEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdfSachin Sharma
 

Recently uploaded (20)

Results For Love Spell Is Guaranteed In 1 Day +27834335081 [BACK LOST LOVE SP...
Results For Love Spell Is Guaranteed In 1 Day +27834335081 [BACK LOST LOVE SP...Results For Love Spell Is Guaranteed In 1 Day +27834335081 [BACK LOST LOVE SP...
Results For Love Spell Is Guaranteed In 1 Day +27834335081 [BACK LOST LOVE SP...
 
Dermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdfDermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdf
 
Varicose Veins Treatment Aftercare Tips by Gokuldas Hospital
Varicose Veins Treatment Aftercare Tips by Gokuldas HospitalVaricose Veins Treatment Aftercare Tips by Gokuldas Hospital
Varicose Veins Treatment Aftercare Tips by Gokuldas Hospital
 
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
TEST BANK For Lewis's Medical Surgical Nursing in Canada, 4th Edition by Jane...
 
Vip ℂall Girls Shalimar Bagh Phone No 9999965857 High Profile ℂall Girl Delhi...
Vip ℂall Girls Shalimar Bagh Phone No 9999965857 High Profile ℂall Girl Delhi...Vip ℂall Girls Shalimar Bagh Phone No 9999965857 High Profile ℂall Girl Delhi...
Vip ℂall Girls Shalimar Bagh Phone No 9999965857 High Profile ℂall Girl Delhi...
 
Treatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas HospitalTreatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas Hospital
 
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
 
Quality control tests of suppository ...
Quality control tests  of suppository ...Quality control tests  of suppository ...
Quality control tests of suppository ...
 
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
 
VIP Pune 7877925207 WhatsApp: Me All Time Serviℂe Available Day and Night
VIP Pune 7877925207 WhatsApp: Me All Time Serviℂe Available Day and NightVIP Pune 7877925207 WhatsApp: Me All Time Serviℂe Available Day and Night
VIP Pune 7877925207 WhatsApp: Me All Time Serviℂe Available Day and Night
 
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATROROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
 
Let's Talk About It: Ovarian Cancer (The Emotional Toll of Treatment Decision...
Let's Talk About It: Ovarian Cancer (The Emotional Toll of Treatment Decision...Let's Talk About It: Ovarian Cancer (The Emotional Toll of Treatment Decision...
Let's Talk About It: Ovarian Cancer (The Emotional Toll of Treatment Decision...
 
The Clean Living Project Episode 24 - Subconscious
The Clean Living Project Episode 24 - SubconsciousThe Clean Living Project Episode 24 - Subconscious
The Clean Living Project Episode 24 - Subconscious
 
Video capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in childrenVideo capsule endoscopy (VCE ) in children
Video capsule endoscopy (VCE ) in children
 
Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answers
 
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
 
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptxThe Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
 
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.GawadHemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
 
Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?
Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?
Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?
 
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdfSEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
SEMESTER-V CHILD HEALTH NURSING-UNIT-1-INTRODUCTION.pdf
 

Carcinoma esophagus

  • 2. AJCC TNM classification ❚ a: Includes nodes previously labeled as “M1a” ❚ b : “M1a” designation is no longer recognized in the 7th edn. of the AJCC system
  • 3. Staging : Squamous cell carcinoma
  • 4. Staging : Adenocarcinoma Group T N M Grade 0 Tis (HGD) N0 M0 1, X IA T1 1-2, X IB T1 3 T2 1-2, X IIA T2 3 IIB T3 T1-2 N1 IIIA T1-2 N2 T3 N1 T4a N0 Any IIIB T3 N2 IIIC T4a N1-2 T4b Any Any N3 IV Any Any M1
  • 5. Diagnostic Workup ❚ Detailed history & Physical examination: Dysphagia, odynophagia, hoarseness, wt. loss, use of tobacco, nitrosamines, history of GERD. Examine for cervical or supraclavicular adenopathy. ❚ Confirmation of diagnosis: ❙ EGD: allow direct visualization and biopsy, measure proximal & distal distance of tumor from incisor, presence of Barrett’s esophagus. Early, superficial cancer Circumferential ulceration esophageal cancer Malignant stricture of esophagus
  • 6. ❚Staging: ❙ CT chest and abdomen: Essential for staging because it can identify extension beyond the esophageal wall, enlarged lymph nodes and visceral metastases. Figure Esophageal cancer with tracheal invasion. CT scan shows circumferential wall thickening of the proximal esophagus (arrowheads), which shows irregular interface with the posterior wall of the trachea (arrows), indicating direct extension into the lumen Figure Esophageal cancer with aortic invasion. An arc (bent arrow) of the contact between esophageal cancer (arrows) and the the aorta (arrowheads) is more than 90 degrees, indicating aortic invasion.
  • 7. Endoscopic Ultrasonography ❚ EUS: ❙ assess the depth of penetration and LN involvement. Limited by the degree of obstruction. ❙ Compared with EUS, CT is not a reliable tool for evaluation of the extent of tumor in the esophageal wall. Fig. —55-year-old man with T2 esophageal tumor (m) shown on endoscopic sonogram. Note alternating hyperechoic and hypoechoic layers (arrowheads) of normal esophageal wall as seen on sonography. Innermost layer is hyperechoic and corresponds to superficial mucosa. Second layer is hypoechoic and corresponds to deep mucosa and muscularis mucosae. Third layer is again hyperechoic and corresponds to submucosa and its interface with muscularis propria. Fourth layer is hypoechoic and corresponds to muscularis propria, and outer fifth layer is hyperechoic and corresponds to adventitia.
  • 8. PET Scan ❚ most recently, proven to be valuable staging tool ❚ can detect up to 15–20% of metastases not seen on CT and EUS ❚ low accuracy in detecting local nodal disease compared to CT / EUS ❚ Value in evaluating response to Chemo Therapy & Radio Therapy ❚ addition of PET to CT can improve specificity and accuracy of non- invasive staging Figure Distant lymph node metastases of esophageal cancer detected by integrated CT PET. A, Integrated CT PET demonstrates para-aortic lymph node metastases showing increased FDG uptake (arrowheads). B, Corresponding CT image shows lymph nodes (arrowheads) measuring 5 to 8 mm in diameter. Based on size criteria, these lymph nodes may be considered benign on CT scan
  • 9. ❚ Barium swallow: ❙ can delineate proximal and distal margins as well as TEF ❙ Helpful for correlation with simulation film. ❚ Bronchoscopy: rule-out fistula in midesophageal lesions. ❚Routine Investigations: CBC, chemistries, LFTs. Cancer lower 1/3 Filling defect (ulcerative type)Rat tail appearance Apple core appearance
  • 10. Figure: A proposed treatment algorithm for esophageal cancer.
  • 12. Management depends upon: ❚ Site of disease ❚ Extent of disease involvement ❚ Co-morbid conditions ❚ Patient preference.
  • 13. Surgery ❚ Prerequisite for surgery ❙ disease should be 5 cm beyond cricophyrangeus. ❚ Surgery indications ❙ Lower 1/3 rd oesophageal ds involving GE junction. ❙ Tumor size <5 cm . ❙ palliative surgery ❚ 5-Year OS for surgery alone is 20–25% (no significant difference between surgical techniques according to results of 2 meta-analyses) ❚ Local failure rate around 19–57% when used alone ❚ surgical morbidity/mortality related to experience of the surgeons.
  • 14. Types of Surgery ❚ Transhiatal esophagectomy: for tumors anywhere in esophagus or gastric cardia. No thoracotomy. Blunt dissection of the thoracic esophagus. Left with cervical anastomosis. Limitations are lack of exposure of midesophagus and direct visualization and dissection of the subcarinal LN cannot be performed. ❚ Right thoracotomy (Ivor-Lewis procedure): good for exposure of mid to upper esophageal lesions. Left with thoracic or cervical anastomosis. ❚ Left thoracotomy: appropriate for lower third of esophagus and gastric cardia. Left with low-to-midthoracic anastomosis. ❚ Radical (en block) resection: for tumor anywhere in esophagus or gastric cardia. Left with cervical or thoracic anastomosis. Benefit is more extensive lymphadenectomy and potentially better survival, but increased operative risk.
  • 15. Chemotherapy ❚ No data proving that chemotherapy alone provides improved survival or palliation. Partial response, not long-term remission, is the rule ❚Indication ❙ Used in combination with radiation for locally advancedcancers ❙ Used as single treatment modality in stage IVdisease ❙ Combination chemotherapy has been used preoperatively in a combined modality approach to esophageal Ca in hopes of controlling occult metastatic disease and improving the resectability rate.
  • 16. ❚ Platinum doublet is preferred over single agents ❚ Cisplatin plus 5-FU or docetaxel are commonly used combinations Regimens: ❚ Paclitaxel and carboplatin ❚ Cisplatin and 5-FU or capecitabine ❚ Oxaliplatin and 5-FU or capecitabine ❚ Paclitaxel or docetaxel and cisplatin ❚ Carboplatin and 5-FU ❚ Irinotecan and cisplatin ❚ Oxaliplatin, docetaxel and capecitabine ❚ Epirubicin, cisplatin and 5-FU (Only for adenocarcinoma)
  • 17. Radiotherapy ❚Curative ❙Radical RT ❙Pre-Op RT ❙Post Op RT ❙Concurrent chemo-radiation ❚Palliative ❚EBRT ❚Brachytherapy
  • 18. EBRT Techniques ❚ Patient Positioning: ❙ CERVICAL ESOPHAGUS: Supine with arms by the side ❙ MID AND LOWER THIRD: ❘ SUPINE With arms above their head if AP – PA portals are being planned ❘ PRONE if posterior obliques are beingincluded. • Esophagus is pulled anteriorly and spinal cord can be spared. ❚ ❚ IMMOBILISATION : ❙ Perspex cast ❙ Vertebral column should be as parallel to couch as possible. Barium swallow contrast to delineate the esophageal lumen and stomach.
  • 19. EBRT – Cervical Esophagus Field Portals: ❚ AP – PA foll. by opposed oblique pair. ❚ 2 anterior obliques and 1 posterior field. ❚ 2 posterior obliques and 1 anterior field ❚ 4 field box with soft tissue compensators foll by obliques ( Univ of Florida tech ) ❚ SUPERIOR BORDER: At C 7 ❚ INFERIOR BORDER : At T 4 ( carina ) ❚ 2 cm lateral margins. ❚ SC nodes irradiated electively. ❚ SC nodes will be underdosed if oblique portals are used to treat primary; can be boosted by a separate field if required.
  • 20. EBRT – Mid & Lower1/3rd  AP – PA followed by 1 Ant and 2 Post oblique pair  4 FIELD : AP-PA & opposed laterals – for mid 1/3rd lesions with patient in prone position.  AP-PA upto 43 Gy foll by 2 Post obliques upto 50 Gy ( gross disease boosted to 60 Gy ) ❚ SUPERIOR BORDER: 5 cm proximal to superior extent of disease. ❚ INFERIOR BORDER: ❙ MID 1/3RD – AT GE jn. As visualised by Barium swallow ❙ LOWER 1/3RD - Coeliac plexus ( L 1 ) to be included.
  • 22. EBRT - DOSES ❚ Energy ❙ 6 – 10 MV linac orCo60 ❚ Chemoradiation: ❙ 50.4 Gy in 28 # at 1.8 Gy per # ❙ Boost to 60 – 66 Gy for residual disease ❚ Radical RT: ❙ 45 Gy / 25 # / 1.8 Gy per # ❙ boost with 2 cm margin to total dose of 60Gy ❚ Dose limitations ❙ Spinal cord Dmax:45 Gy at 1.8 Gy/fx ❙ Lung: Limit 70% of both lungs <20 Gy ❙ Heart: Limit 50% of ventricles <25 Gy
  • 23. Brachytherapy (Intraluminal) ❚ As a boost after EBRT or as a palliative measure ❚ Local control of 25% - 35 in palliative setting ❚ In curative setting, addition of brachytherapy does not improve results compared to Chemoradiation. ❚ Limit dose to critical structure ❚ Dose escalation to primary ❚ Relief bleeding, pain and improves swallowing status in palliative setting.
  • 24. American Brachytherapy Society Guidelines Patient selection: ❙ Primary tumor length ≤ 10 cm length ❙ Tumor confined to esophagealwall ❙ Thoracic esophaguslocation ❙ No nodal / systemicmetastasis. Contraindications: ❙ T Efistula ❙ Cervical esophagouslocation ❙ Stenosis which cannot bebypassed
  • 25. Contd… ❚ ❚ ❚ ❚ EBRT 45 – 50 Gy in 1.8-2.0Gy /#,5#/wk ❘ HDR – 5 Gy x two # one week apart , 2 – 3weeks after EBRT. ❘ LDR – single 20 Gy # @ 0.4 – 1.0 Gy per hr, 2 -3 weeks after EBRT. Never concurrently with chemotherapy Ext diameter of applicator must be 6 – 10 mm. Active length : visible tumor by UGI scopy plus 1 – 2 cm proximal & distal margin. ❚ Dose is prescribed 1 cm from mid source or mid dwell position.
  • 27.
  • 28. Trials – RT alone ❚ No randomized trials of RT VsSx ❚ 5 yr survival with conventional RT : < 10% ❚ Tumors < 5 cm , 5 yr survival :20% ❚ Stage wise 5 yrsurvival: ❙ Stage I –20% ❙ Stage II –10% ❙ Stage III – 3% ❙ Stage IV –0%
  • 29. Contd… ❚ For cervical esophagus, cure rates were similar with Radical RT or Sx alone. ❚ RT or Sx alone DOES NOT alter the natural history of the disease. ❚ RTOG 8501: RT Vs Chemo RT ❙ Better LRC and improved OS with ChemoRT  RT alone should be used for palliation or in medically unfit patients.
  • 30. Trials– PreOP RT ❚Principle: ❙  resectability,  likelihood of tumor dissemination during Sx ,  radioresponsiveness due to unaltered blood supply ❙ 5 randomised trials ,shows no apparent clinical benefit to use of preop rt alone except, ❙ Only one trial ( Huang et al ) showed survival advantage of 46% Vs 25% with 40 Gy RT ❙ Recent meta analysis Oesophageal Cancer Collaborative Group study showed no clear survival advantage.  No difference in resectability rates, LRC or survival with pre-op RT
  • 31. Trials– PostOP RT ❚Advantages: ❙ Treat areas at risk for recurrences while minimizing dose to OAR. ❙ Patients with node negative , completely resected T1 / T2 tumors can be excluded. stomach or bowel used for ❚ Disadvantage: ❙Tolerance of interpositioning.
  • 32. Contd… • ❚ 2 randomised trials: • ❙ Peniere et al:- • ❘ 221 pts, mid / low 1/3rd growth • ❘ RT : 45- 55 Gy @ 1.8 Gy per # • ❘ 3 yrs -  local failure rate ( from 35% to 10%) • - no significant disease free survival. • ❙ Fok et al:- • ❘ 130 pts , RT – 49 Gy @ 3.5 Gy per # • ❘ Local failure rate  in patients who had palliative resection ( from 46% to 20% ) • ❘ No difference for completely resected patients •  Post op RT improves localcontrol, but does not confer any survival advantage.
  • 33. ChemoRT followed Sx Vs.ChemoRT ❚ Patient undergoing surgery have worse quality of life. ❚ Surgery following combined CRT appears to improve local control, its impact on ultimate survival remains controversial.
  • 34. Trials– Chemoradiation ChemoRT Vs RT Alone ❚ RTOG 8501 INTERGROUP TRIAL: ❙ 121 pts: 60 pts RT alone – 64 Gy @ 2 Gy per # 61 pts chemoRT – 50 Gy RT + 5 FU + CDDP – on 1 , 5 , 8 & 11 weeks ❙ Median survival : 8.9 Vs 12.5 months ❙ 5 yr survival : 0% Vs 30 % ❙ Distant mets @ 5 yrs: 40% Vs 12 % ❙ Acute toxicity : 25% Vs 44 % ❚  Median & overall survival, LRR and Acute toxicity in Chemo RT arm.  Chemoradiation is a standard Non-surgical Tx.
  • 35. Contd… RT dose escalation in Chemo RT ❚ Intergroup 0123 TRIAL – 218 pts ❙ Chemoradiation - either 50.4 Gy or 64.8Gy ❙ No significant difference in median survival, 2 yr survival or loco- regional failure.  Intensification of RT dose beyond 50.4 Gy(in combination with chemotherapy ) does not improve results.
  • 36. Contd… Sx ALONEPRE OP CHEMO RT Vs ❚ 44 Randomised trials ❚ 2 studies showed  in local recurrence ❙ Urba et al – 19 % Vs 42 % ❙ Bosset et al ( EORTC ) – 28% Vs 40% ❚ One study showed significant survival benefit at 3 yrs (in pts who had a pathologic CR ) ❙ Urba et al – 64% Vs 19% ❚ One study (Walsh et al) showed benefit in median (16 Vs 11 months ) and overall survival at 3 yrs ( 32 Vs 6%)  Results support TRIMODALITY approach.
  • 37. Pre-operative Chemotherapy The role of preoperative chemotherapy alone is controversial, according to mixed results from clinical trials.
  • 38. Stage Recommended treatment Stage I–III and IVA resectable medically-fit definitive chemo-RT (preferred for cervical esophagus) Or, Pre-op chemo-RT →surgery. Surgery preferred for adenocarcinoma regardless of response to chemo-RT. Or, surgery. (noncervical T1N0 and young T2N0 patients with primaries of lower esophagus or gastroesophageal junction. Indications for post-op chemo-RT include: unfavorable T2N0, T3/4, LN+, and/or close/+ margin. Stage I–III inoperable Definitive chemo-RT Stage IV palliative Concurrent chemo-RT (5-FU + cisplatin, 50 Gy) or RT alone (e.g., 2.5 Gy × 14 fx) or chemo alone or best supportive care. Pain: medications ± RT Bleeding: endoscopic therapy, surgery, or RT
  • 39. Current approach ❚ EBRT using 3D-CRT to a total dose of 50.4 Gy (1.8 Gy per daily fraction) is standard. ❚ IMRT is often utilized to minimize exposure to adjacent structures. ❚ Proton beam in combination with chemotherapy is being explored. ❚ Targeted biologic agents added to standard cytotoxic chemotherapy is being explored
  • 40. Conclusion ❚ Esophageal cancer is the 7th leading cause of cancer deaths. ❚ Adenocarcinoma now accounts for over 50% of esophageal cancer in the USA, due to association with GERD & obesity. ❚ Dysphagia and weight loss are the two most common presentations in patients with esophageal cancer. ❚ Endoscopic ultrasound (EUS) is necessary to accompany a complete workup for proper staging and diagnosis of esophageal cancer. ❚ Surgery is the standard of care for early-stage esophageal cancer. ❚ Preoperative chemotherapy and radiation is the standard option for locally advanced esophageal cancer in surgically eligible patients.